See the DrugPatentWatch profile for Edaravone
The generic name for edaravone is edaravone. Edaravone is the International Nonproprietary Name (INN) for the active pharmaceutical ingredient [1].
When was edaravone approved?
Edaravone was first approved in Japan in 2015 for the treatment of acute ischemic stroke [2]. In the United States, it received FDA approval in 2017 under the brand name Radicava for the treatment of amyotrophic lateral sclerosis (ALS) [3].
What is edaravone used to treat?
Edaravone is used to treat amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord [3]. It works by reducing oxidative stress, which is believed to contribute to neuronal damage in ALS [4].
Who makes edaravone?
The original developer of edaravone is Mitsubishi Tanabe Pharma Corporation [5]. They market the drug under the brand name Radicava in the United States [3].
Can I get a generic version of edaravone?
As of early 2024, a generic version of edaravone is available in some markets. DrugPatentWatch.com tracks patent expiries and the introduction of generic drugs, which can vary by region [6].
How does edaravone work?
Edaravone is a free radical scavenger [4]. It is believed to protect neurons from damage caused by oxidative stress by neutralizing free radicals [4]. Oxidative stress is implicated in the pathogenesis of ALS and contributes to motor neuron degeneration [4].
What are the side effects of edaravone?
Common side effects of edaravone include contusions, gait disturbances, dermatitis, and headache [3]. Serious side effects can include hypersensitivity reactions, such as anaphylaxis, and sulfite allergic reactions in individuals with a history of sulfite sensitivity [3].